Insider Selling: Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Sells 10,000 Shares of Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Thermo Fisher Scientific Price Performance

TMO stock traded up $8.43 during trading on Thursday, reaching $621.77. The company’s stock had a trading volume of 1,393,181 shares, compared to its average volume of 1,565,572. The company’s fifty day moving average is $564.16 and its 200-day moving average is $567.20. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $622.30. The company has a market capitalization of $237.34 billion, a P/E ratio of 39.77, a price-to-earnings-growth ratio of 2.86 and a beta of 0.77. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. During the same period in the previous year, the firm earned $5.15 EPS. The firm’s revenue was down 1.4% compared to the same quarter last year. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.71 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.25%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is 10.01%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Raymond James boosted their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Stifel Nicolaus upped their target price on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Jefferies Financial Group reissued a “buy” rating and issued a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Finally, JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $618.94.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several large investors have recently added to or reduced their stakes in the stock. DAVENPORT & Co LLC boosted its position in shares of Thermo Fisher Scientific by 5.1% during the fourth quarter. DAVENPORT & Co LLC now owns 4,181 shares of the medical research company’s stock valued at $2,219,000 after buying an additional 202 shares during the period. Integrated Investment Consultants LLC lifted its position in shares of Thermo Fisher Scientific by 17.5% during the fourth quarter. Integrated Investment Consultants LLC now owns 720 shares of the medical research company’s stock worth $382,000 after purchasing an additional 107 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 3.0% in the fourth quarter. Venturi Wealth Management LLC now owns 1,097 shares of the medical research company’s stock worth $582,000 after purchasing an additional 32 shares during the last quarter. Heartland Bank & Trust Co lifted its holdings in Thermo Fisher Scientific by 6.0% during the 4th quarter. Heartland Bank & Trust Co now owns 1,132 shares of the medical research company’s stock valued at $601,000 after buying an additional 64 shares in the last quarter. Finally, Trust Point Inc. purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $1,001,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.